| Company* |
Company* |
Type/Product Area |
Terms/Details (Date) |
| November | |||
Shield Holdings AG* (Switzerland) |
AOP Orphan Pharmaceuticals AG (Austria) |
Commercialization deal for STIO-021 in Central Eastern Europe and the Middle East to treat iron deficiency anemia |
Shield gets an up-front payment of €1.25M ($1.74M) and further milestone-based payments of up to €1.75M; AOP gets an equity stake in a Shield subsidiary (11/2) |
| Specialized Therapeutics Australia Pty Ltd.* (Australia) |
Helsinn Healthcare SA (Switzerland) |
Exclusive license and distribution rights for palonosetron from Helsinn in the regions of Australia and New Zealand |
Palonosetron is a 5-HT3 receptor antagonist labeled for prevention of acute nausea and vomiting from chemotherapy (11/2) |
| December | |||
Hemispherx Biopharma Inc. (AMEX:HEB) |
GP Pharma SA (Spain |
Agremeent for the marketing of Alferon N injection in Argentina with an option for other Latin American countries |
Financial terms were not disclosed; Alferon N is approved in the U.S. for sexually transmitted diseases (12/21) |
| Theratechnologies Inc. (Canada; TSX:TH) |
Sanofi-Aventis Group SA (France) |
Commercialization deal for Egrifta in Latin America, Africa and the Middle East |
Theratechnologies will receive a significant percentage of the drug's selling price in those regions, while Sanofi will be responsible for all regulatory and commercial activities for Egrifta for HIV-associated lipodystrophy; it has the option to commercialize the drug in those territories for other indications (12/7) |
| Notes: * Private companies are indicated with an asterisk. The date indicated refers to the BioWorld Today issue in which the news item can be found. Unless otherwise noted, stock symbols listed are on the Nasdaq market. ASX = Australian Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; TSX = Toronto Stock Exchange. | |||
